ACM
KYTX icon

ACT Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

ACT Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356K Buy
40,000
+10,000
+33% +$88.8K 0.23% 45
2026
Q1 		$259K Buy
30,000
+4,900
+20% +$40.8K 0.2% 43
2025
Q4 		$236K Buy
+25,100
New +$186K 0.19% 40

Other funds holding KYTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return
GWM
GSB Wealth Management Guilford, Connecticut $498M AUM 27.51% 1-Year Est. Return

ACT Capital Management's KYTX Position: Q2 2026 in Review

ACT Capital Management increased its Kyverna Therapeutics (KYTX) stake by 33% in Q2 2026, buying an estimated $88.8K and bringing the position to 40,000 shares worth $356K. The position accounts for 0.23% of the portfolio, ranked #45.

ACT Capital Management first reported a position in KYTX in Q4 2025 and has held it in 3 quarters since. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • ACT Capital Management held 40,000 shares of Kyverna Therapeutics worth $356K as of Q2 2026.
  • ACT Capital Management bought 10,000 Kyverna Therapeutics shares in Q2 2026, an estimated $88.8K.
  • Kyverna Therapeutics made up 0.23% of ACT Capital Management's portfolio in Q2 2026, its #45 holding.
  • ACT Capital Management first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.